Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure

Conditions

• Blast Injury

Eligibility Criteria

Sex

MALE

Age

18 Years - 50 Years

Healthy Volunteers

Not accepted

Interventions

• PBR28 TSPO PET — DRUG
  Each SEAL participant will undergo brain imaging with PBR28 translocator protein (TSPO) positron emission tomography (PET) at study enrollment and at 1-year follow up.

Study Details

This is a 4-year, longitudinal study of 100 active-duty Navy SEALs. The goal of the study is to determine whether repeated blast exposure affects SEAL brain health and to develop an initial diagnostic testing protocol that detects repeated blast brain injury.

Key Dates

Start date

Oct 14, 2025

Status verified

Oct 2025

Primary completion

Apr 30, 2029

Completion

Aug 31, 2029

Study Design

Enrollment

100 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Arms

• Experimental: Active-duty United States Navy SEALs
  All SEAL participants will undergo comprehensive, longitudinal assessments of their exposures, cognitive performance, psychological health, physical symptoms, neuroimaging biomarkers, and blood biomarkers.

Primary Outcome Measure

neuroimaging biomarkers [ Time Frame: 1 year ]

Central Contacts

• Brian L Edlow, M.D.
  617-724-6352
  [email protected]
• Michael A Gordon, B.s.
  617-724-6352
  [email protected]

Locations (1)

Find similar trials in Boston, MA